MannaResearch Acquires Montreal Clinical Research Center
MannaResearch, a group of independent clinical research centers, announces the successful acquisition of Kells Medical Research Group, a Montreal-based clinical investigator site.
MannaResearch
, a group of independent clinical research centers, announces the successful acquisition of
Kells Medical Research Group
, a Montreal-based clinical investigator site.
This acquisition represents the fourth Canadian research center MannaResearch has acquired in the past 15 months and its first in Montreal. With more than 15 years of clinical trial experience, Kells Medical Research Group is one of Montreal’s largest primary care research centers and has a database of more than 200,000 patients. The acquisition brings the MannaResearch patient database to 350,000.
Dr. Graham Wood, MannaResearch’s Chief Executive Officer, explains, “Within the industry, the Kells name is synonymous with quality and experience, making the company a perfect fit for MannaResearch. This acquisition represents a strategic addition to our rapidly expanding group of
sites
, helping us attain our goal of simplifying clinical research in Canada for pharmaceutical companies.”
The acquisition supports MannaResearch’s commitment to growth. Over the next few years MannaResearch plans to add additional research sites within Canada to provide its clients access to consistent, high-quality research centers across the nation.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
